AXL activates YAP through the EGFR–LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma
Kento Okamoto, Toshinori Ando, Hiroki Izumi, Susumu Kobayashi, Tomoaki Shintani, J. Silvio Gutkind, Souichi Yanamoto, Mutsumi Miyauchi, Mikihito Kajiya
Topics & Concepts
Hippo signaling pathwayCancer researchHead and neck squamous-cell carcinomaHyperactivationBiologyEGFR inhibitorsEpidermal growth factor receptorCancerSignal transductionCell biologyHead and neck cancerGeneticsHippo pathway signaling and YAP/TAZWnt/β-catenin signaling in development and cancerFibroblast Growth Factor Research